Uveitis Gene-Expression Profiling

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.

Study Overview

• Status: Completed
• Conditions: Uveitis

• Study Type: Observational
• Enrollment (Actual): 280

Contacts and Locations

Study Locations

• United States
  • Oregon
    • Portland, Oregon, United States, 97239-3098
      • Oregon Health & Science University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Individuals suffering from selected subtypes of uveitis, individuals suffering from selected autoimmune disease and healthy individuals.

Description

Inclusion Criteria:

• The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:

  1. ankylosing spondylitis
  2. sarcoidosis
  3. Behçet's disease
  4. toxoplasmosis
  5. herpetic acute retinal necrosis; AND
  6. idiopathic uveitis

• Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:

  1. ankylosing spondylitis
  2. sarcoidosis; AND
  3. Behçet's disease
• The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion Criteria:

• Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

10

Cohorts and Interventions

Group / Cohort
sarcoidosis
ankylosing spondylitis
Behcet's disease
toxoplasmosis
herpetic acute retinal necrosis
idiopathic uveitis
ankylosing spondylitis (no uveitis)
sarcoidosis (no uveitis)
Behcet's disease (no uveitis)
normal control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Correlation of blood transcriptome with form of uveitis	time of office visit for disease evaluation

Collaborators and Investigators

• Sponsor: Oregon Health and Science University
• Investigators: Principal Investigator: James Rosenbaum, MD, Oregon Health and Science University

Study record dates

Study Major Dates

• Study Start: June 1, 2005
• Primary Completion (Actual): July 1, 2010
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: April 1, 2009
• First Submitted That Met QC Criteria: April 1, 2009
• First Posted (Estimate): April 2, 2009

Study Record Updates

• Last Update Posted (Estimate): April 9, 2014
• Last Update Submitted That Met QC Criteria: April 7, 2014
• Last Verified: April 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Uveal Diseases; Uveitis
• Other Study ID Numbers: R01EY015858 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No